Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Listen Now

Bioanalytics
Partner Presentation

Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates

Monday, October 21, 2024
11:00 AM – 12:00 PM MT
Location:360 Stage #4, Exhibit Hall

Sponsored By 
Bioanalytics Partner Presentation-Bioanalytics

    Partner Presentation Speaker(s)

  • Li Qu, Ph.D

    Associate Director, Non-GLP Bioanalysis
    WuXi AppTec
    Shanghai, Shanghai, China (People's Republic)

  • Peng Li, PhD (he/him/his)

    Senior Scientist, MetID
    WuXi AppTec
    Nanjing, Jiangsu, China (People's Republic)

Description: This presentation will explore the comprehensive evaluation of Antibody-Drug Conjugates (ADCs) through integrated bioanalysis and advanced biotransformation studies. Key topics include nonclinical pharmacokinetic assessment, metabolite profiling, Drug-to-Antibody Ratio (DAR) analysis and strategies to ADC complexities throughout analysis. Attendees will gain insights into leveraging multiple analytical platforms and hybrid methods to overcome challenges in ADC drug bioanalysis, facilitating the ADC drug R&D process.

Learning Objectives:

  • Understand the role of integrated bioanalysis in nonclinical pharmacokinetic evaluation of ADCs
  • Learn advanced methodologies for ADC biotransformation, including metabolite profiling and DAR analysis
  • Explore strategies to overcome challenges in ADC development using comprehensive analytical approaches